Advertisement

Epidemiological screening and xenomonitoring for human lymphatic filariasis infection in select districts in the states of Maharashtra and Karnataka, India

  • Vishal Khatri
  • Nitin Amdare
  • Nikhil Chauhan
  • Namdev Togre
  • Maryada V. Reddy
  • Subhash L. Hoti
  • Ramaswamy KalyanasundaramEmail author
Helminthology - Short Communication

Abstract

Lymphatic filariasis (LF) is a mosquito-transmitted tropical neglected parasitic infection that currently affects over 120 million people around the world and another 856 million people are at risk of acquiring the infection. Mass Drug Administration (MDA) spearheaded by the World Health Organization is the only current strategy to control this infection in endemic areas. In this study, we performed an epidemiological survey in select regions in the southern parts of India to determine the current status of LF infection in subjects. Night blood samples were collected from 916 subjects after proper consent and were screened for the presence of circulating microfilariae of Wuchereria bancrofti in their peripheral blood. Our results showed the presence of 51 (5.56%) cases of human LF infection in the surveyed areas including new cases for LF, which were not recorded previously. Given the presence of new cases of LF infections, we trapped mosquitoes from these regions and screened for the presence of W. bancrofti L3 specific Ssp1 DNA repeat sequences by PCR. Our results confirmed the presence of LF infection in the mosquitoes collected from six out of nine districts that we surveyed. These findings confirm active transmission of LF infection in all of the areas that we surveyed, despite several years of MDA treatment. The findings in this study suggest potential reemergence of LF infection in most of the areas we surveyed and warrants for a more stringent strategy for controlling LF in these endemic areas.

Keywords

Lymphatic filariasis Mosquitoes PCR Night blood screening Reemergence of infection India 

Notes

Funding information

This work was supported in part by the Nehru Fulbright Scholar Program awarded to RK and by the National Institutes of Health, National Institute of Allergy and Infectious Diseases grants R01AI072613 (RK).

References

  1. Alhassan A, Li Z, Poole CB, Carlow CK (2015) Expanding the MDx toolbox for filarial diagnosis and surveillance. Trends Parasitol 31:391–400.  https://doi.org/10.1016/j.pt.2015.04.006 CrossRefGoogle Scholar
  2. Anil N (2012) Assessing coverage of mass drug administration against lymphatic filariasis in Gulbarga district, Karnataka. Int J Med Public Health 2:25CrossRefGoogle Scholar
  3. Awadzi K, Adjepon-Yamoah KK, Edwards G, Orme ML, Breckenridge AM, Gilles HM (1986) The effect of moderate urine alkalinisation on low dose diethylcarbamazine therapy in patients with onchocerciasis. Br J Clin Pharmacol 21:669–676CrossRefGoogle Scholar
  4. Babayan SA, Allen JE, Taylor DW (2012) Future prospects and challenges of vaccines against filariasis. Parasite Immunol 34:243–253.  https://doi.org/10.1111/j.1365-3024.2011.01350.x CrossRefGoogle Scholar
  5. Babu BV, Kar SK (2004) Coverage, compliance and some operational issues of mass drug administration during the programme to eliminate lymphatic filariasis in Orissa, India. Tropical Med Int Health 9:702–709.  https://doi.org/10.1111/j.1365-3156.2004.01247.x CrossRefGoogle Scholar
  6. Bennuru S, Nutman TB (2009) Lymphatics in human lymphatic filariasis: in vitro models of parasite-induced lymphatic remodeling. Lymphat Res Biol 7:215–219.  https://doi.org/10.1089/lrb.2009.0022 CrossRefGoogle Scholar
  7. Bhattacharjee J (2016) Mass drugs administration in India-a failure story. Epidemiology: Open Access 6Google Scholar
  8. Brady M (2014) Seventh meeting of the global alliance to eliminate lymphatic filariasis: reaching the vision by scaling up, scaling down, and reaching out. Parasit Vectors 7:46.  https://doi.org/10.1186/1756-3305-7-46 CrossRefGoogle Scholar
  9. Chambers EW et al (2009) Xenomonitoring of Wuchereria bancrofti and Dirofilaria immitis infections in mosquitoes from American Samoa: trapping considerations and a comparison of polymerase chain reaction assays with dissection. Am J Trop Med Hyg 80:774–781CrossRefGoogle Scholar
  10. Das D, Kumar S, Sahoo PK, Dash AP (2005) A survey of bancroftian filariasis for microfilariae & circulating antigenaemia in two villages of Madhya Pradesh. Indian J Med Res 121:771–775Google Scholar
  11. El-Setouhy M et al (2007) The effect of compliance on the impact of mass drug administration for elimination of lymphatic filariasis in Egypt. Am J Trop Med Hyg 77:1069–1073CrossRefGoogle Scholar
  12. Hawking F, World Health Organization (1978) Diethylcarbamazine: a review of the literature with special reference to its pharmacodynamics, toxicity, and use in the therapy of onchocerciasis and other filarial infections. http://www.who.int/iris/handle/10665/70735
  13. Krentel A, Fischer PU, Weil GJ (2013) A review of factors that influence individual compliance with mass drug administration for elimination of lymphatic filariasis. PLoS Negl Trop Dis 7:e2447.  https://doi.org/10.1371/journal.pntd.0002447 CrossRefGoogle Scholar
  14. Kumar A, Kumar P, Nagaraj K, Nayak D, Ashok L, Ashok K (2009) A study on coverage and compliance of mass drug administration programme for elimination of filariasis in Udupi district, Karnataka, India. J Vector Borne Dis 46:237–240Google Scholar
  15. Nujum ZT, Remadevi S, Nirmala C, Rajmohanan K, Indu P, Nair SM (2012) Factors determining noncompliance to mass drug administration for lymphatic filariasis elimination. Trop Parasitol 2:109–115.  https://doi.org/10.4103/2229-5070.105175 CrossRefGoogle Scholar
  16. NVBDCP NVBDCP (2011) National roadmap for elimination of lymphatic filariasis (NRELF) directorate of national vector borne disease control program. http://nvbdcp.gov.in/WriteReadData/l892s/National-Roadmap-ELF.pdf. Accessed February 17 2018
  17. NVBDCP NVBDCP (2014) National guidelines for transmission assessment survey. Directorate of National Vector Borne Disease Control Program. http://nvbdcp.gov.in/WriteReadData/l892s/TAS-National-Guidelines-2013-14.pdf. Accessed April 04 2018
  18. Patel PK (2012) Mass drug administration coverage evaluation survey for lymphatic filariasis in bagalkot and Gulbarga districts. Indian J Community Med 37:101–106.  https://doi.org/10.4103/0970-0218.96095 CrossRefGoogle Scholar
  19. Raju K, Jambulingam P, Sabesan S, Vanamail P (2010) Lymphatic filariasis in India: epidemiology and control measures. J Postgrad Med 56:232–238.  https://doi.org/10.4103/0022-3859.68650 CrossRefGoogle Scholar
  20. Ramaiah KD, Ottesen EA (2014) Progress and impact of 13 years of the global programme to eliminate lymphatic filariasis on reducing the burden of filarial disease. PLoS Negl Trop Dis 8:e3319.  https://doi.org/10.1371/journal.pntd.0003319 CrossRefGoogle Scholar
  21. Ramaiah KD, Thiruvengadam B, Vanamail P, Subramanian S, Gunasekaran S, Nilamani N, Das PK (2009) Prolonged persistence of residual Wuchereria bancrofti infection after cessation of diethylcarbamazine-fortified salt programme. Tropical Med Int Health 14:870–876.  https://doi.org/10.1111/j.1365-3156.2009.02307.x CrossRefGoogle Scholar
  22. Schwab AE, Boakye DA, Kyelem D, Prichard RK (2005) Detection of benzimidazole resistance-associated mutations in the filarial nematode Wuchereria bancrofti and evidence for selection by albendazole and ivermectin combination treatment. Am J Trop Med Hyg 73:234–238CrossRefGoogle Scholar
  23. Schwab AE, Churcher TS, Schwab AJ, Basanez MG, Prichard RK (2006) Population genetics of concurrent selection with albendazole and ivermectin or diethylcarbamazine on the possible spread of albendazole resistance in Wuchereria bancrofti. Parasitology 133:589–601.  https://doi.org/10.1017/S003118200600076X CrossRefGoogle Scholar
  24. Silumbwe A, Zulu JM, Halwindi H, Jacobs C, Zgambo J, Dambe R, Chola M, Chongwe G, Michelo C (2017) A systematic review of factors that shape implementation of mass drug administration for lymphatic filariasis in sub-Saharan Africa. BMC Public Health 17:484.  https://doi.org/10.1186/s12889-017-4414-5 CrossRefGoogle Scholar
  25. Sunish IP, Munirathinam A, Kalimuthu M, Ashok Kumar V, Tyagi BK (2014) Persistence of lymphatic filarial infection in the paediatric population of rural community, after six rounds of annual mass drug administrations. J Trop Pediatr 60:245–248.  https://doi.org/10.1093/tropej/fmt101 CrossRefGoogle Scholar
  26. Toothong T, Tipayamongkholgul M, Suwannapong N, Suvannadabba S (2015) Evaluation of mass drug administration in the program to control imported lymphatic filariasis in Thailand. BMC Public Health 15:975.  https://doi.org/10.1186/s12889-015-2325-x CrossRefGoogle Scholar
  27. WHO (2010) Progress report 2000-2009 and strategic plan 2010-2020 of the global programme to eliminate lymphatic filariasis: halfway towards eliminating lymphatic filariasis. World Health Organization. http://whqlibdoc.who.int/publications/2010/9789241500722_eng.pdf. Accessed May 04 2018
  28. WHO (2018) Lymphatic filariasis. World Health Organization. http://www.who.int/lymphatic_filariasis/elimination-programme/en. Accessed January 6 2018
  29. Wiwanitkit S, Wiwanitkit V (2011) Mass drug administration for elimination of lymphatic filariasis: a discussion. J Vector Borne Dis 48:182 author reply 182Google Scholar
  30. Zolnikov TR (2018) Vector-borne disease. In: Autoethnographies on the environment and human health. Springer, pp 113–126Google Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of Biomedical SciencesUniversity of Illinois College of MedicineRockfordUSA
  2. 2.Albert Einstein College of MedicineMontefiore Medical CenterBronxUSA
  3. 3.Department of BiochemistryMahatma Gandhi Institute of Medical SciencesSevagramIndia
  4. 4.Regional Medical Research CentreIndian Council of Medical ResearchBelgaumIndia
  5. 5.Department of Biomedical SciencesUniversity of Illinois College of MedicineRockfordUSA

Personalised recommendations